Stock information

Stock information

Neola Medical AB (publ) listed the company’s share on Nasdaq First North Growth Market in Stockholm on October 2, 2020. Neola Medical AB (publ) is a record company and its shares are registered in electronic form with Euroclear Sweden AB, where its share register is also kept. All shares are of the same type, have an equal right to a share in the Company’s assets and profits and have the same voting value. All shares are issued and fully paid up.

The company’s share is traded under the short name NEOLA.

The company’s ISIN code for the share is: SE0014829255

ISIN code for warrants TO1 is: SE0014731006

The share price and trading in the share can be followed on Nasdaq First North Growth Market Stockholm.

For questions regarding the distribution of acquisition values for Gasporox and Neola Medical, please see Gasporox’s website: https://www.gasporox.se/pressreleases/aktieinformation/

 

The share

Share owners

Development in the share capital

Year Transaction Quota value Change in no. of shares Change in share capital Total no. of shares Total share capital
2016 Incorporation 1,00 50 000 50 000 50 000 50 000
2017 New share issue 1,00 33 333 33 333 83 333 83 333
2020 Bonus issue 6,00 0 416 667 83 333 500 000
2020 Split 0,036 13 916 611 0 13 999 944 500 000
2020 New share issue 0,036 18 786 671 14 018 730 500 671
2020 Reverse split 0,071 2:1 251 117 10 524 990 751 788
2020 New share issue 0,071 3 515 625 251 117 10 524 990 1 499 062
2021 Preferential rights issue 0,071 10 524 990 747 274 21 049 980 1 499 062

Incentive programs

There are currently three (3) incentive programs in Neola Medical.

  • Warrants 2021/2025A (for senior executives, other employees and consultants in the Company) that was decided at the Annual General Meeting on May 20, 2021. During the exercise period, which runs from and including 2 June 2025 to and including 30 June 2025, these may be used for subscription of newly issued shares in the Company.
  • Warrants 2021/2025B (for board members) that was decided at the Annual General Meeting on May 20, 2021. During the exercise period, which runs from and including 2 June 2025 to and including 30 June 2025, these may be used for subscription of newly issued shares in the Company.
  • LTI 2022/2026 (for chief executive officer) that was decided at the Extra General Meeting on September 27, 2022. The incentive programme will run for a period of four full financial years, i.e. from January 1 to December 31, during 2022 – 2025.

 

Subscribe